ICCC Immucell Corp

  1. Stocks
  2. Healthcare
  3. NASDAQ: ICCC

Price (delayed)

$9.865

Market cap

$89.25M

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$0.07

Enterprise value

$95.21M

?
Relative Growth: Rel. Growth: 53
Relative Strength: Rel. Strength: 87
Relative Valuation: Rel. Valuation: 19
Relative Profitability: Rel. Profitability: 33

ImmuCell Corporation's purpose is to create scientifically proven and practical products that improve the health and productivity of dairy and beef cattle. ImmuCell manufactures and markets First Defense®, providing Immediate ...

Highlights
ICCC's gross profit is up by 42% YoY and by 11% QoQ
ICCC's quick ratio is up by 34% since the previous quarter and by 18% year-on-year
The net income has dropped by 101% year-on-year but it rose by 48% since the previous quarter
ICCC's EPS is up by 42% since the previous quarter but it is down by 40% year-on-year
Sector: Healthcare
Industry: Biotechnology
Website: http://www.immucell.com
Peers: IDXX WOOF MRK ZTS

Key stats

What are the main financial stats of ICCC

ICCC stock price

How has the Immucell stock price performed over time
Intraday
1.23%
1 week
5.17%
1 month
-2.52%
1 year
48.35%
YTD
60.41%
QTD
55.85%

Financial performance

How have Immucell's revenue and profit performed over time
Revenue
$29.93M
Gross profit
$12.75M
Operating income
$2.5M
Net income
-$545,403
Gross margin
42.6%
Net margin
-1.8%
The net income has dropped by 101% year-on-year but it rose by 48% since the previous quarter
Immucell's net margin has plunged by 80% YoY but it has soared by 53% from the previous quarter
The operating income has soared by 52% since the previous quarter
ICCC's gross profit is up by 42% YoY and by 11% QoQ

Price vs fundamentals

How does ICCC's price correlate with its fundamentals

Growth

What is Immucell's growth rate over time

Valuation

What is Immucell stock price valuation
P/E
N/A
P/B
3.06
P/S
2.98
EV/EBIT
N/A
EV/EBITDA
46.25
EV/Sales
3.18
ICCC's EPS is up by 42% since the previous quarter but it is down by 40% year-on-year
The stock's P/B is 70% more than its 5-year quarterly average of 1.8 and 53% more than its last 4 quarters average of 2.0
The company's equity rose by 8% QoQ
The stock's P/S is 49% more than its last 4 quarters average of 2.0 and 19% more than its 5-year quarterly average of 2.5
Immucell's revenue has increased by 10% YoY and by 8% QoQ

Efficiency

How efficient is Immucell business performance
ICCC's ROIC has dropped by 120% year-on-year but it is up by 45% since the previous quarter
The ROA has dropped by 100% year-on-year but it is up by 48% since the previous quarter
The company's return on equity has shrunk by 90% YoY but it rose by 47% QoQ
ICCC's return on sales has dropped by 70% year-on-year but it has surged by 54% since the previous quarter

Dividends

What is ICCC's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for ICCC.

Financial health

How did Immucell financials performed over time
ICCC's total assets is 195% higher than its total liabilities
ICCC's quick ratio is up by 34% since the previous quarter and by 18% year-on-year
Immucell's current ratio has increased by 17% YoY and by 13% from the previous quarter
Immucell's debt is 56% less than its equity
The company's debt to equity fell by 14% YoY and by 10% QoQ
Immucell's debt has decreased by 13% YoY and by 3.2% from the previous quarter

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.